SUBSCRIBE
SUBSCRIBE

Synexa Life Sciences

Synexa Life Sciences is a biomarker and bioanalytical lab CRO, specialising in the development, validation and delivery of a wide range of complex and custom-designed assays.

With a team of over 200 staff across three global laboratory locations; Manchester, Turku (Finland) and Cape Town, we provide innovative solutions to support our customers to achieve their clinical milestones.

Our main areas of expertise include biomarker identification and development, large and small molecule clinical bioanalysis, (soluble) biomarker analysis (utilising MSD, LC-MS/MS, ELISA, RIA, fluorescence and luminescence-based technologies), cell biology (including flow cytometry, ELISpot and Fluorospot) and genomic services to support clinical trials and translational studies.

We pride ourselves on our deep scientific expertise and ability to tackle complex problems, translating them into robust and reliable assays to support clinical trial sample analysis.

NEWS
FDA
FDA Removes Black Box Warning From HRT Products, Reversing Landmark Decision
After a leading study caused the FDA to slap its most stringent warning on hormone replacement therapies for menopause more than two decades ago, the regulator is changing course in what FDA Commissioner Marty Makary called a “historic day for women in the United States.”
November 10, 2025
 · 
2 min read
 · 
Heather McKenzie
Obesity
Despite Obesity Drug Pricing Deal, GLP-1 Compounders Continue To Operate in the Shadows
The White House may have struck a deal with Eli Lilly and Novo Nordisk last week to lower the costs of their weight loss drugs for patients, but knockoff versions of Zepbound and Wegovy still permeate the obesity market.
November 10, 2025
 · 
3 min read
 · 
Dan Samorodnitsky
Digital illustration of human eye color modification and futuristic vision. Made with vector vibrant color gradient geometry form. Isolated on colorful textured background.
Gene therapy
Lilly Doubles Down on Eye Diseases, Adding to BD Spree
MeiraGTx Holdings is licensing a genetic eye disease medicine to Eli Lilly in a deal worth up to $475 million.
November 10, 2025
 · 
1 min read
 · 
Annalee Armstrong
Modern collage with human heart and hands stock illustration
Cardiovascular disease
Ionis’ Tryngolza ‘Game-Changing’ in Lowering Triglycerides, Cementing Case for FDA Filing
Ionis is planning a supplemental submission by the end of the year to expand Tryngolza into severe hypertriglyceridemia. If granted, William Blair expects the antisense drug to be “transformational” for this indication.
November 10, 2025
 · 
2 min read
 · 
Tristan Manalac
Amgen sign at its headquarters in Thousand Oaks, California, USA.
Cardiovascular disease
Amgen’s Repatha Cuts Risk of First Heart Attack by 36% in Phase III Trial
The cholesterol-lowering drug is part of a suite of medicines that also includes MariTide and that Amgen Chief Medical Officer Paul Burton hopes will make the company the “undisputed leader in the management of cardiometabolic risk for patients” by 2030.
November 10, 2025
 · 
4 min read
 · 
Heather McKenzie
Indianapolis, U.S. - April 16, 2016: Eli Lilly and Company World Headquarters. Lilly makes Medicines and Pharmaceuticals VII
Metabolic disorders
Lilly Makes $1.2B RNAi Pact With SangeneBio, Targets Metabolic Diseases
Eli Lilly has been on a dealmaking spree this year, with a few deals worth $1 billion or more. Aside from SangeneBio, these include SiteOne, Verve and Scorpion.
November 10, 2025
 · 
2 min read
 · 
Tristan Manalac
ransparent plastic tube being blocked by orange balls on blue background. Illustration of the concept of digestive disorders and difficulties on career paths
Cardiovascular disease
Merck Builds Case for Cholesterol-Lowering Pill With Injectable-Like Efficacy
Multiple analyst firms were impressed by the Phase III data, which showed that Merck’s oral PCSK9 inhibitor can lower low-density lipoprotein cholesterol by more than 55% after 24 weeks.
November 10, 2025
 · 
2 min read
 · 
Tristan Manalac
Differen. A disagreement in business strategy or vision between leaders.
Mergers & acquisitions
Pfizer’s Winning Bid for Metsera Concludes ‘Real Housewives of Biopharma’
The deal is done. What happens next for Pfizer and Metsera—and Novo?
November 10, 2025
 · 
3 min read
 · 
Annalee Armstrong
Hair damaged Repair Solution concept, Nourish hair of shampoo or serum
Drug Development
From Weight Loss to Hair Loss: The Search for the Next Blockbuster
A new generation of companies is eyeing the existing, sizeable hair loss market, hoping that better formulations and new scientific targets will finally produce treatments that are safer and more effective, as well as commercially successful.
November 10, 2025
 · 
6 min read
 · 
Ben Hargreaves
Load More
Visit website
Email Us
IN THE PRESS
Press Releases
Waters Sets a New Benchmark for Robustness and Sensitivity for High-Throughput Labs with the Xevo TQ Absolute XR Mass Spectrometer
June 2, 2025
 · 
4 min read
BioMidwest
Inotiv, Inc. Announces New Site Openings and Expansions Supporting Additional Capacity and Service Offerings
December 8, 2022
 · 
4 min read
Business
Parexel Announces Strategic Collaboration with Synexa Life Sciences and Drawbridge Health for COVID-19 Clinical Serology Testing Solution
November 2, 2020
 · 
4 min read
JOBS